Respiratory Syncytial Virus Infection Acute Respiratory Infection, Respiratory Syncytial Virus
Conditions
Interventions
None listed
Sponsors
kamiya hajime
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. children residing in Mie prefecture who were born between November 1, 2024 and December 31, 2026. ymptoms other than rsv infection. 2. children who are not eligible for health insurance coverage for Nirsevimab(children who do not meet any of the following conditions) during the early phase of the first RSV epidemic season after birth: newborns and infants aged 12 months or younger who were born at a gestational age of 28 weeks or less newborns and infants aged 6 months or younger who were born at a gestational age of 29 to 35 weeks during the early phase of the first and second RSV epidemic seasons after birth newborns and children aged 24 months or younger who received treatment for chronic lung disease within the past 6 months newborns, infants, and children aged 24 months or younger with congenital heart disease with hemodynamic abnormalities newborns, infants, and children aged 24 months or younger with immunodeficiency newborns, infants, and children aged 24 months or younger with down syndrome 3. children who present with lower respiratory tract disease and who sought medical care within 14 days after symptom onset. 4. children who tested positive for RSV by rapid antigen test or PCR test, or children who meet conditions 1 through 3 and visited the same medical institution on the same day as a child who tested positive for RSV by rapid antigen test or PCR test, for symptoms other than RSV infection.
Exclusion criteria
Exclusion criteria: 1. Children who are eligible for health insurance coverage for nirsevimab. 2. Children with a previous history of RSV infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effectiveness of nirsevimab | — |
Contacts
Public Contacttomoyuki uno
Mie University Graduate School of Medicine
Outcome results
None listed